Latest Avastin Stories
LONDON (Reuters) - Combining the drug Avastin with standard chemotherapy can keep breast cancer under control for longer in patients with advanced disease, scientists said on Wednesday. Avastin, which is made by Roche Holding AG and its majority-owned U.S. biotech arm Genentech Inc, blocks the growth of new blood vessels that are needed for the cancer to grow and spread, or metastasize, beyond the breast. When doctors combined the drug with the chemotherapy treatment Taxol in a study...
CHICAGO (Reuters) - Genentech Inc. said on Tuesday early results from a mid-stage trial show that combining lung cancer drug Tarceva with Avastin works no better than Avastin alone in patients with advanced kidney cancer, sending shares of Tarceva partner OSI Pharmaceuticals Inc. down 7 percent. As a result, the world's No. 2 biotechnology company said it will not pursue further studies of the Avastin/Tarceva combination in kidney cancer but will continue to analyze the results of the...
Nov. 30--Genentech's cancer drug Avastin helped boost survival for patients with colorectal cancer by two months, researchers announced Monday. While the gains in median survival were modest, the large-scale study sponsored by the National Cancer Institute underscores the effectiveness of the drug in prolonging the lives of some of the sickest patients with one of the deadliest forms of cancer. The new findings could boost sales of Avastin, which reached $183 million for the quarter...
SAN FRANCISCO -- Genentech Inc. said Monday its novel colon cancer-fighting drug Avastin helped some of the sickest patients stay alive two months longer than expected, giving the drug an additional boost on its way to blockbuster status. The South San Francisco-based biotechnology titan made the announcement ahead of a major conference for cancer researchers and doctors scheduled for January, when the company said it would release more detailed results from a large-scale human experiment...
SOUTH SAN FRANCISCO, Calif. and BASEL, Switzerland, Nov. 29 /PRNewswire-FirstCall/ -- Genentech, Inc. and Roche (SWX Zurich) today announced that a randomized Phase III study of Avastin(TM) (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival. Results from an interim analysis demonstrated that patients receiving Avastin...
